Regenxbio

Novartis announced the Phase III STEER study met its primary endpoint, showing improved motor function in SMA patients treated with OAV101 IT. Plans to share results with regulators in 2025 aim to make the therapy available for SMA patients.

The Age-related Vision Dysfunction Market report by DelveInsight forecasts trends, treatments, and epidemiology from 2020 to 2034, highlighting key companies and therapies. It covers conditions like AMD, glaucoma, and diabetic retinopathy, emphasizing the need for innovative treatments in aging populations.

The Phase III STEER study showed OAV101 IT improved motor function in SMA patients, with a favorable safety profile. Novartis plans to share results with regulatory agencies in 2025 to make the therapy available.

Novartis announced positive Phase III STEER study results for OAV101 IT, showing improved motor function in SMA patients aged two and older. Plans to share findings with regulatory agencies in 2025 aim to make the therapy available for SMA patients.

The Phase III STEER study demonstrated OAV101 IT's efficacy in increasing HFMSE scores in SMA patients aged 2-18, showing better motor function versus sham controls. With a favorable safety profile, Novartis aims to share results with regulatory agencies by 2025 to make OAV101 IT available for SMA patients.

The Phase III STEER study demonstrated that intrathecal onasemnogene abeparvovec (OAV101 IT) significantly improved motor function in SMA patients aged two and older, as measured by HFMSE scores. With a favorable safety profile, Novartis aims to submit results to regulatory agencies by 2025, seeking approval for OAV101 IT to treat SMA.

AbbVie outperforms BriaCell Therapeutics in revenue, earnings, and institutional ownership, with a higher consensus target price and lower volatility. Analysts favor AbbVie for its stronger financials and market position, making it the more favorable stock compared to BriaCell Therapeutics.

UniQure's gene therapy AMT-130 for Huntington's disease may qualify for FDA accelerated approval, based on ongoing trial data compared to an external control group. The FDA suggested using a known scale for Huntington's progression and neurofilament light chain reductions as evidence of effectiveness. UniQure's stock doubled following this news.